Last reviewed · How we verify
AG2304T
AG2304T is a small molecule targeting the PD-1 receptor.
AG2304T is a small molecule targeting the PD-1 receptor. Used for Metastatic non-small cell lung cancer, PD-L1 positive, Metastatic melanoma.
At a glance
| Generic name | AG2304T |
|---|---|
| Sponsor | Ahn-Gook Pharmaceuticals Co.,Ltd |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
By binding to PD-1, AG2304T prevents its interaction with its ligands, PD-L1 and PD-L2, thereby releasing the brakes on T-cell activation and proliferation, leading to enhanced anti-tumor immune responses.
Approved indications
- Metastatic non-small cell lung cancer, PD-L1 positive
- Metastatic melanoma
Common side effects
- Fatigue
- Diarrhea
- Nausea
- Rash
- Pruritus
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AG2304T CI brief — competitive landscape report
- AG2304T updates RSS · CI watch RSS
- Ahn-Gook Pharmaceuticals Co.,Ltd portfolio CI